Aldagen, Inc.
Aldagen's work stems from the need for tissue repair. The biopharmaceutical company develops cell regeneration therapies using adult stem cells. It uses a proprietary technology that isolates an enzyme known as aldehyde dehydrogenase, or ALDH, which it believes can target a number of diseases. Aldagen hopes its products will be used to treat hereditary metabolic diseases in children, leukemia, and cardiovascular diseases; all its drugs are in the development stage. The company does its own manufacturing and plans to do its own marketing. Venture capital firm Intersouth Partners holds about 42% of Aldagen, which filed an IPO in late 2009. The company is led by CEO W. Thomas Amick.
Contact Details
Office Address
Aldagen, Inc.
2810 Meridian Parkway, Suite 148
Durham, NC, USA 27713
Phone: (919) 484-2571
Fax: (919) 484-8792
Executives
Chairman and CEO
W. Thomas Amick
President and COO
Edward L. Field